{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:27:59Z","timestamp":1790126879219,"version":"4.0.1"},"reference-count":101,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CTN01_00177_817708"],"award-info":[{"award-number":["CTN01_00177_817708"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Molecular and clinical heterogeneity is increasingly recognized as a common characteristic of neurodegenerative diseases (NDs), such as Alzheimer\u2019s disease, Parkinson\u2019s disease and amyotrophic lateral sclerosis. This heterogeneity makes difficult the development of early diagnosis and effective treatment approaches, as well as the design and testing of new drugs. As such, the stratification of patients into meaningful disease subgroups, with clinical and biological relevance, may improve disease management and the development of effective treatments. To this end, omics technologies\u2014such as genomics, transcriptomics, proteomics and metabolomics\u2014are contributing to offer a more comprehensive view of molecular pathways underlying the development of NDs, helping to differentiate subtypes of patients based on their specific molecular signatures. In this article, we discuss how omics technologies and their integration have provided new insights into the molecular heterogeneity underlying the most prevalent NDs, aiding to define early diagnosis and progression markers as well as therapeutic targets that can translate into stratified treatment approaches, bringing us closer to the goal of personalized medicine in neurology.<\/jats:p>","DOI":"10.3390\/ijms22094820","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T21:35:39Z","timestamp":1619904939000},"page":"4820","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases"],"prefix":"10.3390","volume":"22","author":[{"given":"Valentina","family":"La Cognata","sequence":"first","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council (CNR), 95126 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Morello","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council (CNR), 95126 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7590-1792","authenticated-orcid":false,"given":"Sebastiano","family":"Cavallaro","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council (CNR), 95126 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/jclinpath-2019-205952","article-title":"Molecular pathology of neurodegenerative diseases: Principles and practice","volume":"72","author":"Kovacs","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"ref_2","first-page":"30","article-title":"Clinicopathological overlap of neurodegenerative diseases: A comprehensive review","volume":"78","author":"Das","year":"2020","journal-title":"J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"m3752","DOI":"10.1136\/bmj.m3752","article-title":"Rethinking monogenic neurological diseases","volume":"371","author":"Chen","year":"2020","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fnagi.2017.00166","article-title":"Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology","volume":"9","author":"Santiago","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13073-021-00878-y","article-title":"Emerging genetic complexity and rare genetic variants in neurodegenerative brain diseases","volume":"13","author":"Perrone","year":"2021","journal-title":"Genome Med."},{"key":"ref_7","first-page":"3","article-title":"New hopes and challenges for treatment of neurodegenerative disorders: Great opportunities for young neuroscientists","volume":"4","author":"Kiaei","year":"2013","journal-title":"Basic Clin. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yiannopoulou, K.G., Anastasiou, A.I., Zachariou, V., and Pelidou, S.H. (2019). Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines, 7.","DOI":"10.20944\/preprints201909.0270.v1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s41649-021-00165-3","article-title":"Perceptions of \u2018Precision\u2019 and \u2018Personalised\u2019 Medicine in Singapore and Associated Ethical Issues","volume":"13","author":"Ong","year":"2021","journal-title":"Asian Bioeth. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/14636778.2019.1637720","article-title":"Contested futures: Envisioning \u201cPersonalized,\u201d \u201cStratified,\u201d and \u201cPrecision\u201d medicine","volume":"38","author":"Erikainen","year":"2019","journal-title":"New Genet. Soc."},{"key":"ref_11","first-page":"e12001","article-title":"Biomarker potential of brain-secreted extracellular vesicles in blood in Alzheimer\u2019s disease","volume":"12","author":"Badhwar","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3233\/JAD-160975","article-title":"The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer\u2019s Disease Diagnosis: The Italian Selfie","volume":"55","author":"Sancesario","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/bib\/bbw114","article-title":"Genome, transcriptome and proteome: The rise of omics data and their integration in biomedical sciences","volume":"19","author":"Manzoni","year":"2018","journal-title":"Brief. Bioinforma."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"590742","DOI":"10.3389\/fimmu.2021.590742","article-title":"High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery","volume":"12","author":"Zielinski","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Olivier, M., Asmis, R., Hawkins, G.A., Howard, T.D., and Cox, L.A. (2019). The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194781"},{"key":"ref_17","unstructured":"Kumar, A., Sidhu, J., Goyal, A., and Tsao, J.W. (2020). Alzheimer Disease. StatPearls, StatPearls Publishing."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1093\/hmg\/ddq160","article-title":"Molecular mechanisms of neurodegeneration in Alzheimer\u2019s disease","volume":"19","author":"Crews","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0891988710383571","article-title":"Genetics of Alzheimer disease","volume":"23","author":"Bekris","year":"2010","journal-title":"J. Geriatr. Psychiatr. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000452256","article-title":"From Common to Rare Variants: The Genetic Component of Alzheimer Disease","volume":"81","author":"Nicolas","year":"2016","journal-title":"Hum. Hered."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A Unique Microglia Type Associated with Restricting Development of Alzheimer\u2019s Disease","volume":"169","author":"Spinrad","year":"2017","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JAD-2012-120637","article-title":"Validation of AclarusDx\u2122, a Blood-Based Transcriptomic Signature for the Diagnosis of Alzheimer\u2019s Disease","volume":"32","author":"Sol","year":"2012","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_24","first-page":"1","article-title":"AlzGPS: A genome-wide positioning systems platform to catalyze multi-omics for Alzheimer\u2019s drug discovery","volume":"13","author":"Zhou","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_25","first-page":"1","article-title":"A multi-omic atlas of the human frontal cortex for aging and Alzheimer\u2019s disease research","volume":"5","author":"Ma","year":"2018","journal-title":"Sci. Data"},{"key":"ref_26","first-page":"1","article-title":"An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer\u2019s disease","volume":"13","author":"Clark","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ebiom.2019.08.051","article-title":"Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer\u2019s disease: The INSIGHT-preAD study","volume":"47","author":"Xicota","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41588-020-0696-0","article-title":"An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer\u2019s disease","volume":"52","author":"Nativio","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.neuron.2019.12.015","article-title":"Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer\u2019s Disease Progression","volume":"105","author":"Bai","year":"2020","journal-title":"Neuron"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.nic.2005.09.008","article-title":"The Alzheimer\u2019s disease neuroimaging initiative","volume":"15","author":"Mueller","year":"2005","journal-title":"Neuroimaging Clin. N. Am."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2174\/156720512801322573","article-title":"Overview and findings from the religious orders study","volume":"9","author":"Bennett","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2019.1456","article-title":"Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype","volume":"76","author":"Ma","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dagan, H., Flashner-Abramson, E., Vasudevan, S., Jubran, M.R., Cohen, E., and Kravchenko-Balasha, N. (2020). Exploring Alzheimer\u2019s Disease Molecular Variability via Calculation of Personalized Transcriptional Signatures. Biomolecules, 10.","DOI":"10.3390\/biom10040503"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Milind, N., Preuss, C., Haber, A., Ananda, G., Mukherjee, S., John, C., Shapley, S., Logsdon, B.A., Crane, P.K., and Carter, G.W. (2020). Transcriptomic stratification of late-onset Alzheimer\u2019s cases reveals novel genetic modifiers of disease pathology. PLoS Genet., 16.","DOI":"10.1371\/journal.pgen.1008775"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"eabb5398","DOI":"10.1126\/sciadv.abb5398","article-title":"Molecular subtyping of Alzheimer\u2019s disease using RNA sequencing data reveals novel mechanisms and targets","volume":"7","author":"Neff","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20639","article-title":"Subgroups of Alzheimer\u2019s disease based on cerebrospinal fluid molecular markers","volume":"58","author":"Iqbal","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2019.08.032","article-title":"Biomarker-guided clustering of Alzheimer\u2019s disease clinical syndromes","volume":"83","author":"Toschi","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lerche, S., Schulte, C., Wurster, I., Machetanz, G., Roeben, B., Zimmermann, M., Deuschle, C., Hauser, A.K., Bohringer, J., and Krageloh-Mann, I. (2021). The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PDGBA. Move. Disord. Off. J. Move. Disord. Soc.","DOI":"10.1002\/mds.28472"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-019-0033-1","article-title":"An omics-based strategy using coenzyme Q10 in patients with Parkinson\u2019s disease: Concept evaluation in a double-blind randomized placebo-controlled parallel group trial","volume":"1","author":"Prasuhn","year":"2019","journal-title":"Neurol. Res. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101772","DOI":"10.1016\/j.pneurobio.2020.101772","article-title":"Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson\u2019s disease","volume":"187","author":"Carling","year":"2020","journal-title":"Prog. Neurobiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fnagi.2018.00326","article-title":"The Luxembourg Parkinson\u2019s Study: A Comprehensive Approach for Stratification and Early Diagnosis","volume":"10","author":"Hipp","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jamaneurol.2020.5257","article-title":"Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets","volume":"78","author":"Kia","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2014.12.002","article-title":"Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex","volume":"74","author":"Aronica","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fneur.2017.00152","article-title":"Molecular Taxonomy of Sporadic Amyotrophic Lateral Sclerosis Using Disease-Associated Genes","volume":"8","author":"Morello","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.celrep.2019.09.066","article-title":"Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia","volume":"29","author":"Tam","year":"2019","journal-title":"Cell Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ymgme.2011.11.201","article-title":"ALS patients with mutations in the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations","volume":"105","author":"Wuolikainen","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Chen, Q., Sandhu, D., Konrad, C., Roychoudhury, D., Schwartz, B.I., Cheng, R.R., Bredvik, K., Kawamata, H., Calder, E.L., and Studer, L. (2018). Identification of a Distinct Metabolomic Subtype of Sporadic ALS Patients. bioRxiv, 416396.","DOI":"10.1101\/416396"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13195-018-0455-y","article-title":"Heterogeneity of Alzheimer\u2019s disease: Consequence for drug trials?","volume":"10","author":"Devi","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.18632\/aging.101638","article-title":"The heterogeneity within Alzheimer\u2019s disease","volume":"10","author":"Ferreira","year":"2018","journal-title":"Aging"},{"key":"ref_50","first-page":"602","article-title":"Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer\u2019s disease","volume":"4","author":"Liu","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13024-020-0358-9","article-title":"Therapeutic approaches targeting Apolipoprotein E function in Alzheimer\u2019s disease","volume":"15","author":"Williams","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JAD-161070","article-title":"Genetic Stratification to Identify Risk Groups for Alzheimer\u2019s Disease","volume":"57","author":"Marioni","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1038\/s41380-018-0298-8","article-title":"Genetic data and cognitively defined late-onset Alzheimer\u2019s disease subgroups","volume":"25","author":"Mukherjee","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41598-020-57785-2","article-title":"Novel Alzheimer\u2019s disease subtypes identified using a data and knowledge driven strategy","volume":"10","author":"Mitelpunkt","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Nazarian, A., Yashin, A.I., and Kulminski, A.M. (2020). Summary-Based Methylome-Wide Association Analyses Suggest Potential Genetically Driven Epigenetic Heterogeneity of Alzheimer\u2019s Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051489"},{"key":"ref_56","first-page":"83","article-title":"Systems medicine and the integration of bioinformatic tools for the diagnosis of Alzheimer\u2019s disease","volume":"1","author":"Oresic","year":"2009","journal-title":"Genome Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"595","DOI":"10.18632\/aging.100801","article-title":"Metabolic profiling distinguishes three subtypes of Alzheimer\u2019s disease","volume":"7","author":"Bredesen","year":"2015","journal-title":"Aging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3233\/JAD-150336","article-title":"Targeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer\u2019s Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer\u2019s Disease","volume":"48","author":"Wood","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Czech, C., Berndt, P., Busch, K., Schmitz, O., Wiemer, J., Most, V., Hampel, H., Kastler, J., and Senn, H. (2012). Metabolite profiling of Alzheimer\u2019s disease cerebrospinal fluid. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031501"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/brain\/awz384","article-title":"A multiomics approach to heterogeneity in Alzheimer\u2019s disease: Focused review and roadmap","volume":"143","author":"Bellec","year":"2020","journal-title":"Brain J. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/pr5000895","article-title":"Plasma Metabolite Profiles of Alzheimer\u2019s Disease and Mild Cognitive Impairment","volume":"13","author":"Wang","year":"2014","journal-title":"J. Proteome Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ejn.14094","article-title":"The clinical heterogeneity of Parkinson\u2019s disease and its therapeutic implications","volume":"49","author":"Greenland","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s13760-020-01473-5","article-title":"Genetics of Parkinson\u2019s disease","volume":"120","author":"Cherian","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00439-016-1749-4","article-title":"Copy number variability in Parkinson\u2019s disease: Assembling the puzzle through a systems biology approach","volume":"136","author":"Morello","year":"2017","journal-title":"Hum. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00702-017-1707-x","article-title":"Classification of advanced stages of Parkinson\u2019s disease: Translation into stratified treatments","volume":"124","author":"Klucken","year":"2017","journal-title":"J. Neural Transm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fnagi.2017.00301","article-title":"Parkinson\u2019s Disease Subtypes Identified from Cluster Analysis of Motor and Non-motor Symptoms","volume":"9","author":"Mu","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","article-title":"Developing and validating Parkinson\u2019s disease subtypes and their motor and cognitive progression","volume":"89","author":"Lawton","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jnnp-2012-303455","article-title":"Parkinson\u2019s disease subtypes: Lost in translation?","volume":"84","author":"Marras","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11910-017-0738-x","article-title":"Subtypes of Parkinson\u2019s Disease: What Do They Tell Us About Disease Progression?","volume":"17","author":"Fereshtehnejad","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jnnp.2003.033530","article-title":"Heterogeneity of Parkinson\u2019s disease in the early clinical stages using a data driven approach","volume":"76","author":"Lewis","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Beeler, J.A., Erro, R., Vitale, C., Amboni, M., Picillo, M., Moccia, M., Longo, K., Santangelo, G., De Rosa, A., and Allocca, R. (2013). The Heterogeneity of Early Parkinson\u2019s Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070244"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","article-title":"Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease","volume":"76","author":"Lees","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_73","first-page":"1","article-title":"Precision medicine in Parkinson\u2019s disease patients with LRRK2 and GBA risk variants\u2014Let\u2019s get even more personal","volume":"9","author":"Brundin","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JPD-140507","article-title":"Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review","volume":"5","author":"Gasser","year":"2015","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/brain\/aww109","article-title":"Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: A pharmacogenetic study","volume":"139","author":"Masellis","year":"2016","journal-title":"Brain J. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/mds.26558","article-title":"Alpha-synuclein gene variants may predict neurostimulation outcome","volume":"31","author":"Weiss","year":"2016","journal-title":"Move. Disord."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/mds.28195","article-title":"GBA-Related Parkinson\u2019s Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort","volume":"35","author":"Petrucci","year":"2020","journal-title":"Move. Disord. Off. J. Move. Disord. Soc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1172\/JCI126120","article-title":"Precision medicine: Discovering clinically relevant and mechanistically anchored disease subgroups at scale","volume":"129","author":"Rosen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic Lateral Sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature","volume":"41","author":"Logroscino","year":"2013","journal-title":"Neuroepidemiology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1212\/NXG.0000000000000239","article-title":"Determining the incidence of familiality in ALS","volume":"4","author":"Ryan","year":"2018","journal-title":"Neurol. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1358\/dot.2018.54.6.2828189","article-title":"Edaravone: A new hope for deadly amyotrophic lateral sclerosis","volume":"54","author":"Bhandari","year":"2018","journal-title":"Drugs Today"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s40262-018-0655-4","article-title":"Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics","volume":"57","author":"Dash","year":"2018","journal-title":"Clin. Pharmacokineti."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fnagi.2017.00068","article-title":"ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?","volume":"9","author":"Petrov","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/14656566.2017.1319937","article-title":"Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis","volume":"18","author":"Sawada","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: From genes to mechanism","volume":"539","author":"Taylor","year":"2016","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2741\/e811","article-title":"Transcriptomics in amyotrophic lateral sclerosis","volume":"10","author":"Krokidis","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fneur.2019.00400","article-title":"A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS","volume":"10","author":"Vijayakumar","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"9968","DOI":"10.1038\/s41598-019-46355-w","article-title":"Integrative multi-omic analysis identifies new drivers and pathways in molecularly distinct subtypes of ALS","volume":"9","author":"Morello","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"La Cognata, V., Gentile, G., Aronica, E., and Cavallaro, S. (2020). Splicing Players Are Differently Expressed in Sporadic Amyotrophic Lateral Sclerosis Molecular Clusters and Brain Regions. Cells, 9.","DOI":"10.3390\/cells9010159"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3389\/fneur.2018.01126","article-title":"Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS","volume":"9","author":"Lanznaster","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JAD-190132","article-title":"Low Serum High-Density Lipoprotein Cholesterol Levels Associate with the C9orf72 Repeat Expansion in Frontotemporal Lobar Degeneration Patients","volume":"72","author":"Solje","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Guillemin, G.J., Blasco, H., Patin, F., Descat, A., Gar\u00e7on, G., Corcia, P., Gel\u00e9, P., Lenglet, T., Bede, P., and Meininger, V. (2018). A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198116"},{"key":"ref_95","first-page":"e2089","article-title":"Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis","volume":"92","author":"Bjornevik","year":"2019","journal-title":"Neurology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4155\/fmc.15.60","article-title":"Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: Implications for personalized therapy","volume":"7","author":"Morello","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.2174\/0929867322666150408112135","article-title":"Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling","volume":"22","author":"Morello","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/jcsm.12422","article-title":"Histaminergic transmission slows progression of amyotrophic lateral sclerosis","volume":"10","author":"Apolloni","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3389\/fimmu.2017.01689","article-title":"Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis","volume":"8","author":"Apolloni","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"101121","DOI":"10.1016\/j.arr.2020.101121","article-title":"Omics-based exploration and functional validation of neurotrophic factors and histamine as therapeutic targets in ALS","volume":"62","author":"Volonte","year":"2020","journal-title":"Ageing Res. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ruffini, N., Klingenberg, S., Schweiger, S., and Gerber, S. (2020). Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale. Cells, 9.","DOI":"10.20944\/preprints202010.0393.v1"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4820\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:56:36Z","timestamp":1760162196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":101,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ijms22094820"],"URL":"https:\/\/doi.org\/10.3390\/ijms22094820","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}